Company: HSDTW
Filing Date: 2025-05-02
Form Type: DEF 14A
Source: 0001104659-25-044128
Chunk: 4

Company: Solana Co
Filing Date: 2025-05-02
Form: DEF 14A
Chunk 4
---
 ​ | 27 | ​ | ​ |

i

TABLE OF CONTENTS

#### HELIUS MEDICAL TECHNOLOGIES, INC.PROXY STATEMENT

#### 2025 SPECIAL MEETING OF STOCKHOLDERSMay 23, 2025

### QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING

#### Who is soliciting my vote?
The Board of Directors (the “

#### Board
”) of Helius Medical Technologies, Inc. (the “

#### Company
”, “

#### we
” or “

#### us
”) is soliciting your proxy, as a holder of our Class A common stock (the “

#### Common Stock
”), for use at the special meeting of stockholders to be held on May 23, 2025, at 9:00 a.m. Eastern Time, virtually at www.virtualshareholdermeeting.com/HSDT2025SM and any adjournment or postponement of such meeting (the “

#### Special Meeting
”). We have engaged Alliance Advisors, LLC to assist in the solicitation of proxies.

The Notice of Special Meeting of Stockholders (the “

#### Notice
”), proxy statement and form of proxy card are expected to be first mailed to stockholders of record on or about May 2, 2025.

#### What is the purpose of the Special Meeting?
At the Special Meeting, you will be voting on:

•

Proposal 1: To approve an amendment to our Certificate of Incorporation to effect a reverse split of our outstanding Class A common stock at a ratio of 1-to-2 to 1-to-250 to be determined at the discretion of our Board of Directors, whereby each outstanding 2 to 250 shares would be combined, converted and changed into 1 share of our Class A common stock, to enable the Company to comply with the Nasdaq Stock Market’s continued listing requirements;

•

Proposal 2: To approve an amendment to our Certificate of Incorporation, to increase the number of authorized shares of our Common Stock to up to 800,000,000 shares, with such number to be determined at the Board’s discretion (the “

#### Authorized Share Increase Proposal
”);

•

Proposal 3: To approve, pursuant to Nasdaq Listing Rule 5635(d), the potential issuance of shares of our Common Stock in a potential financing;

•

Proposal 4: To approve an amendment to the Helius Medical Technologies, Inc, 2022 Equity Incentive Plan; and

•

Proposal 5: To